To Get more Insights,  Request A Free Sample 

Market Dynamics 

Driver: Increasing Regulatory Approvals for Gene Therapy Products Accelerating Cancer Treatment Innovation and Patient Access

The landscape of cancer gene therapy is rapidly evolving, driven by a surge in regulatory approvals for innovative treatments. This acceleration is evident in the approval of nine cell and gene therapies (CGTs) for various cancers across the United States and the European Union, with a primary focus on autologous CAR-T cell therapies for hematological cancers. The FDA's commitment to expediting the availability of these groundbreaking treatments is further demonstrated in the cancer gene therapy market by the approval of 55 novel therapeutics in 2023, marking the second-highest count in the past 30 years. This includes several gene therapies for cancer, highlighting the agency's dedication to advancing cutting-edge treatments.

The impact of this driver extends beyond mere numbers, as it signifies a paradigm shift in cancer treatment approaches. The FDA has approved over 300 accelerated approval applications, many of which are cancer therapies, including four gene therapies. This accelerated approval pathway in the cancer gene therapy market is crucial for bringing promising therapies to patients more quickly, especially in oncology where time is of the essence. The diversification of gene therapy trials is also noteworthy, with 51% of newly initiated gene therapy trials now targeting non-oncology indications, up from 39% in previous years. This shift indicates a broadening scope of gene therapy applications, although oncology remains a significant focus. The establishment of the FDA's new super office, the Office of Therapeutic Products (OTP), is designed to streamline workflow processes and improve efficiencies within the agency, further supporting the regulatory review of cell and gene therapies. These developments collectively underscore the growing acceptance and integration of gene therapies into mainstream cancer treatment protocols, promising more innovative and effective options for patients in the near future. 

Trend: Development of Novel Non-Viral Vectors for Gene Delivery Enhancing Safety and Efficacy in Cancer Therapy

The development of novel non-viral vectors for gene delivery in the cancer gene therapy market is a rapidly evolving trend in cancer gene therapy, driven by the need for safer and more efficient alternatives to viral vectors. This trend is characterized by the exploration of various non-viral vector technologies, including lipid nanoparticles (LNPs), polymeric nanoparticles, and single-chain cyclic polymers (SCKPs). LNPs, in particular, have gained significant attention due to their successful application in mRNA-based COVID-19 vaccines, demonstrating their potential in gene therapy applications. In cancer therapy, LNPs are being investigated for delivering siRNA and mRNA to target tumor cells, with ongoing clinical trials evaluating their efficacy and safety.

The advancement of polymeric nanoparticles, such as poly(amidoamine) (PAMAM) dendrimers and polyethyleneimine (PEI), represents another facet of this trend in the cancer gene therapy market. These nanoparticles offer high gene loading capacity and favorable safety profiles, making them promising candidates for cancer gene therapy. Recent studies have shown that PAMAM dendrimers can effectively deliver siRNA to glioblastoma cells, resulting in significant tumor growth inhibition. Additionally, the development of single-chain cyclic polymers (SCKPs) as a novel class of non-viral vectors offers improved gene encapsulation and delivery efficiency. SCKPs have been shown to form compact nanoparticles with enhanced stability and reduced aggregation in physiological conditions. The use of functional non-viral vectors, which incorporate targeting and imaging capabilities, has also been explored to increase specificity and monitor gene delivery in real-time. These innovations in non-viral vector technology are paving the way for more effective and safer gene therapy approaches in cancer treatment, addressing key challenges such as delivery efficiency and specificity that have historically limited the clinical application of gene therapy.

Challenge: Non-Specific Expression and Low-Efficiency Delivery Hindering Precision and Effectiveness in Cancer Gene Therapy

The challenge of non-specific expression and low-efficiency delivery in cancer gene therapy market presents significant obstacles to achieving precise and effective treatments. Non-specific expression refers to the unintended activation of therapeutic genes in non-target tissues, which can lead to off-target effects and toxicity. This issue is particularly pronounced with the use of viral vectors, which often result in widespread distribution beyond the intended tumor site. For instance, the use of strong viral promoters like the CMV promoter can induce gene expression in both cancerous and normal cells, compromising the specificity of the treatment. To address this, researchers are developing tumor-specific promoters that are overexpressed in cancer cells, such as the human telomerase reverse transcriptase (hTERT) promoter, which has shown promise in limiting expression to cancerous cells.

The low-efficiency delivery of therapeutic genes to cancer cells further compounds the challenge. Traditional viral vectors, while effective, pose risks of immunogenicity and insertional mutagenesis. Non-viral vectors, such as nanoparticles and liposomes, offer a safer alternative but often suffer from low transfection efficiency, with gene transfer efficiencies reported to be 1/10th to 1/1000th of viral vectors in the cancer gene therapy market. This inefficiency is primarily due to difficulties in cellular uptake and endosomal escape. Recent advancements in nanotechnology, such as the use of iron-based nanomaterials, have shown promise in enhancing the delivery efficiency of non-viral vectors by improving cellular uptake and targeting capabilities. These nanomaterials can be engineered to enhance gene delivery through magnetic targeting and photothermal effects. Additionally, the development of stimuli-responsive delivery systems, which release their payload in response to specific environmental triggers within the tumor, represents a promising strategy to overcome delivery challenges. Despite these advancements, achieving high efficiency and specificity in gene delivery remains a critical hurdle in translating cancer gene therapies from preclinical models to successful clinical applications.

Segmental Analysis 

By Therapy: Gene-Induced Immunotherapy Takes the Center Stage

Gene-induced immunotherapy with over 41% market share is widely recognized as the largest and most prominent modality in the cancer gene therapy market, a status strongly supported by data from reputable sources such as the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC). According to the WHO’s 2020 Global Cancer Observatory (GLOBOCAN), there were approximately 19.3 million new cancer cases worldwide, with cancer accounting for nearly 10 million deaths. In light of these alarming figures, immunotherapy options that leverage genetic modification of immune cells—particularly T cells—have gained remarkable traction. One core example is CAR-T (chimeric antigen receptor T-cell) therapy, which has achieved response rates upwards of 80% in certain hematologic malignancies (e.g., acute lymphoblastic leukemia). This exceptional efficacy is cited by multiple clinical trials, some of which are referenced by the National Cancer Institute (NCI), a division of the U.S. National Institutes of Health (NIH). Additional gene-driven immunotherapies include T-cell receptor (TCR) therapies and tumor-infiltrating lymphocytes (TIL) therapies, both of which also boast substantial success in advanced clinical trials.

The scope of these therapies in the cancer gene therapy market extends beyond leukemia and lymphoma, targeting solid tumors such as melanoma, breast cancer, and lung cancer—some of the most prevalent and high-burden cancers worldwide. From a market perspective, the appeal of gene-induced immunotherapy lies in its personalized approach and transformative efficacy profile, which often results in durable disease remission, fewer long-term complications, and strong overall survival benefits. Hospitals and oncology centers have increasingly adopted such treatments given the potential for significant healthcare savings over the patient’s lifetime—a fact underscored by evaluation data from various health economics studies. Notably, the CDC has highlighted an evolving trend in which immunotherapy for cancer is advancing from experimental to mainstream therapy. This is fueled by growing research investments, robust collaborations between academic institutions and pharma companies, and supportive regulatory pathways. Consequently, gene-induced immunotherapies are not only leading the charge in clinical outcomes but also solidifying their reputation as a mainstay in the global cancer gene therapy market.

By End Users: Biopharmaceutical Companies Steering Market Growth 

Biopharmaceutical companies have emerged as the leading force in the cancer gene therapy market, capturing more than 46% of market revenue share. This dominance stems primarily from substantial investments in research and development (R&D), a fact that is evident from the billions of dollars allocated annually to oncology-focused pipelines. The U.S. National Institutes of Health (NIH) indicates that industry-sponsored clinical trials account for a significant portion of the trials conducted nationwide, many revolving around gene therapies. These companies often leverage advanced gene-editing technologies, including CRISPR/Cas9, to refine therapeutic safety and efficacy. Notably, they employ rigorous quality control in manufacturing processes, enabling the mass production of complex cellular products such as CAR-T cells. This scale of production meets the high demand for innovative oncology treatments and reduces the overall cost per therapy, which ultimately appeals to hospitals and payers. Indeed, cost-effectiveness data—supported by organizations like the Agency for Healthcare Research and Quality (AHRQ)—reinforces the economic viability of these treatments over the long term, particularly when reduced relapse rates are factored in.

From a global distribution standpoint, biopharmaceutical giants in the cancer gene therapy market maintain extensive sales and logistics networks, ensuring that new therapies can rapidly penetrate both developed and emerging markets. This wide-reaching pipeline also benefits from collaborations with academic and governmental institutions. Such alliances bolster scientific credibility, facilitate data-sharing, and expedite regulatory approvals due to pooled resources and expertise. Furthermore, many of these companies actively partner with the U.S. Food and Drug Administration (FDA) to implement accelerated approval pathways, underscoring their pivotal role in swiftly bringing novel cancer gene therapies to patients. 

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America’s overarching command of the cancer gene therapy market, accounting for more than 62% of total revenues globally (as cited by various market intelligence reports and some figures shared in WHO’s 2020 updates), is underpinned by significant financial commitment to healthcare innovation, robust clinical-research infrastructures, and a well-structured regulatory environment. The United States in particular stands out as the major stakeholder within this region, largely due to the interplay of several contributory factors: billions of dollars in public and private funding, an active venture capital ecosystem, and the presence of top-tier academic medical centers that excel in both translational medicine and large-scale trials. According to the CDC, the U.S. commits over US$200 billion annually to cancer care when considering both direct and indirect costs, illustrating the scope of its focus on advanced therapies. Additionally, data from the American Cancer Society (ACS) underscores the urgent demand, with about 1.9 million new cancer diagnoses reported in 2022 and an estimated 608,570 related deaths. In response to these figures, the U.S. has been expanding programs and grants that concentrate on gene-based immunotherapeutic strategies to tackle diverse cancer types, ranging from hematological malignancies to major solid tumor indications like lung and breast cancer.

An essential driver of this remarkable uptake is the relative stringency and efficiency of FDA approval pathways designed to fast-track breakthrough therapies, particularly those with strong efficacy evidence in Phase II or III clinical trials. This system in the cancer gene therapy market reduces bureaucratic delays and sets a clear framework for manufacturers, reinforcing investor confidence. Furthermore, the healthcare ecosystem in the U.S. is distinguished by well-established insurance reimbursements, including backed coverage from Medicare and major private insurers for select gene therapies that have demonstrated robust clinical benefits. Considering the burden of cancer within the country, which the CDC estimates will rise as the population ages, the U.S. market for gene therapy will likely continue to experience strong demand. This is bolstered by enhanced patient and physician awareness, widespread screening initiatives, and greater acceptance of precision medicine approaches. As a result, North America—especially the United States—stands as a linchpin in the global cancer gene therapy marketplace, shaping not only the present landscape but also setting the trajectory for future developments in this transformative area of oncology.

Recent Developments in Cancer Gene Therapy Market

• In December 2023, Pfizer completed a monumental acquisition of Seagen Inc., a global biotechnology company specializing in transformative cancer medicines, for approximately $43 billion. This acquisition significantly enhances Pfizer's oncology portfolio, particularly with Seagen's proprietary Antibody-Drug Conjugate (ADC) technology, which is a powerful tool in cancer treatment. This move represents a major consolidation in the cancer gene therapy industry and demonstrates the high value placed on innovative cancer treatment technologies.
• In January 2024, Kyowa Kirin successfully acquired Orchard Therapeutics, a leader in gene therapy for rare diseases, including cancer-related conditions. This acquisition allows Kyowa Kirin to expand its portfolio with Orchard's hematopoietic stem cell gene therapy platform, which has potential applications in cancer gene therapy. This development highlights the growing interest in gene therapy platforms that can be applied to multiple conditions, including cancer.
• In March 2024, Capstan Therapeutics, a company involved in cell therapy closely related to cancer gene therapy, raised $175 million in an oversubscribed Series B financing round. This substantial funding is indicative of the strong investor interest in companies developing innovative therapies in the gene therapy space. It demonstrates the continued financial support for advanced research and development in cancer gene therapies, even in later-stage companies.
• In October 2024, the Alliance for Regenerative Medicine reported that investments in cell and gene therapies reached $10.9 billion in the first half of 2024, surpassing the total investments of 2019. This resurgence in investment is primarily directed towards later-stage companies with advanced clinical trials, indicating a focus on companies with promising therapeutic candidates. This development shows a significant increase in financial backing for cancer gene therapies and related fields, reflecting growing confidence in their potential.
• In October-December 2024, the FDA approved Obecabtagene autoleucel (Aucatzyl), a new CAR T-cell therapy designed to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This therapy uses a unique antibody fragment to target CD19, potentially reducing severe immune toxicities associated with previous CAR T-cell therapies. This approval represents a significant advancement in cancer gene therapy, offering a potentially safer and more effective treatment option for patients with this aggressive form of leukemia.

Top Companies in Cancer Gene Therapy Market:

• Abeona Therapeutics Inc.
• Adaptimmune Limited
• Aduro Biotech
• Altor Bioscience Inc.
• Asklepios BioPharmaceutical Inc.
• BioCancell Inc.
• Bluebird bio Inc.
• Bristol Myers
• CelgeneInc
• Elevate BioInc
• Genelux Corporation
• GenVec
• GSK plc.
• Introgen TherapeuticsInc
• MerckKGaA
• Novartis AG
• OncoGenex Pharmaceuticals Inc.
• Orchard Therapeutics Plc
• Other Prominent Players

Market Segmentation Overview:

By Therapy

• Gene Induced Immunotherapy
• Gene Transfer
• Oncolytic Virotherapy

By End-User 

• Biopharmaceutical Companies
• Diagnostic centers
• Hospitals
• Research Institutes
• Others

By Region 

• North America
  • The USA
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America